StreetInsider.com News Articles

Form SCHEDULE 13G/A CAPRICOR THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC

Wed, 14 Oct 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20261014/27187883.html

Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)

Thu, 08 Oct 2026 04:50:48 -0400

Oppenheimer analyst Leland Gershall reiterated an Outperform rating and $54.00 price target on Capricor Therapeutics (NASDAQ: CAPR).

The analyst comments "Today's webinar reviewed incremental information (details inside) submitted to FDA within the BLA amendment. Most interesting in our view was robustness work around HOPE-3's primary endpoint whereby >600 alternative analyses support a ~1-point treatment effect over placebo—arguing for deramiocel efficacy on upper limb function irrespective of how the data are treated. Integrated HOPE-2/HOPE-3 efficacy analyses show a 1.29 point PUL 2.0 benefit at Month 12 (p=0.0087), for which eight sensitivity analyses were all significant at p<0.02. Month 12 LVEF data favor

Caprock Provides 2026 Operational Highlights and an Update on its 2027 Work Program at Destiny

Wed, 07 Oct 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to provide an overview of its operational highlights in fiscal 2026, and an update on its plans for the upcoming year at its flagship Destiny gold property ("Destiny", or the "Property", or the "Project"), located near Val d'Or, Quebec.

Caprock's President & CEO, Mr. Vishal Gupta, commented, "2026 was a year of milestones for Caprock - strengthening the Company's board of directors with the appointment of Jean-David Moore, completing our maiden drill program, intersecting high grade mineralization, and proving out our thesis

Caprock Provides 2026 Operational Highlights and an Update on its 2027 Work Program at Destiny

Wed, 07 Oct 2026 07:30:00 -0400

Capricor's DMD drug slows upper limb decline in 24-month study

Mon, 05 Oct 2026 09:02:53 -0400

Capricor Therapeutics (NASDAQ: CAPR) presented data from the HOPE-3 open-label extension study showing that patients with Duchenne muscular dystrophy (DMD) who switched from placebo to its experimental drug Deramiocel experienced a 76% reduction in the rate of upper limb decline during their first year on the treatment, compared with their prior year on placebo.

The data were presented at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan. The study enrolled 106 patients, with 98 entering the open-label extension phase. Among patients who received Deramiocel for both years of the study, the rate of upper limb decline remained

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

Mon, 05 Oct 2026 09:00:00 -0400

-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year-

-At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts-

-Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026-

-Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data-

SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

Mon, 05 Oct 2026 09:00:00 -0400

-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year-

-At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts-

-Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026-

-Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data-

SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a

Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR) Ahead of Presentaion

Thu, 17 Sep 2026 10:28:42 -0400

Oppenheimer analyst Leland Gershall reiterated an Outperform rating and $54.00 price target on Capricor Therapeutics (NASDAQ: CAPR) after the company announced that 24-month results from the Phase 3 HOPE-3 trial will be presented at the upcoming World Muscle Society Congress (9/29 - 10/3).

The analyst commented, "CAPR announced that 24-month results from the Phase 3 HOPE-3 trial will be presented at the upcoming World Muscle Society Congress (9/29 - 10/3). Recall that the latter half of these results, consisting of one year of open-label data showing skeletal and cardiac outcomes in patients receiving deramiocel, form the core of deramiocel's BLA

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

Thu, 17 Sep 2026 08:30:00 -0400

– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA –

– PDUFA Target Action Date of November 22, 2026 –

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Company’s lead asset for the treatment of Duchenne muscular dystrophy (DMD), will be presented in a

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

Thu, 17 Sep 2026 08:30:00 -0400

– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA –

– PDUFA Target Action Date of November 22, 2026 –

Form SCHEDULE 13G CAPRICOR THERAPEUTICS, Filed by: MILLENNIUM MANAGEMENT LLC

Mon, 14 Sep 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260914/27059658.html

B.Riley Upgrades Capricor Therapeutics (CAPR) to Buy

Mon, 14 Sep 2026 03:51:34 -0400

(Updated - September 14, 2026 3:51 AM EDT)

B.Riley analyst Madison El-Saadi upgraded Capricor Therapeutics (NASDAQ: CAPR) from Neutral to Buy with a price target of $21.00.

The analyst comments "We are upgrading Capricor Therapeutics, Inc. (CAPR) from Neutral to Buy and raising our PT from $5 to $21, as we think the asymmetric setup favors owning shares into the 11/22/26 PDUFA, with potential for an OLE data-driven re-rating before the FDA binary that we think could come as soon as World Muscle Society (WMS) conference on 10/3. We see 50% upside in a positive scenario at WMS, and expect shares to

B.Riley Upgrades Capricor Therapeutics (CAPR) to Buy

Mon, 14 Sep 2026 03:51:34 -0400

(Updated - September 14, 2026 3:51 AM EDT)

B.Riley analyst Madison El-Saadi upgraded Capricor Therapeutics (NASDAQ: CAPR) from Neutral to Buy with a price target of $21.00.

B.Riley Upgrades Capricor Therapeutics (CAPR) to Buy

Mon, 14 Sep 2026 03:51:34 -0400

(Updated - September 14, 2026 3:51 AM EDT)

B.Riley analyst Madison El-Saadi upgraded Capricor Therapeutics (NASDAQ: CAPR) from Neutral to Buy with a price target of $21.00.

B.Riley Upgrades Capricor Therapeutics (CAPR) to Buy

Mon, 14 Sep 2026 03:51:34 -0400

(Updated - September 14, 2026 3:51 AM EDT)

B.Riley analyst Madison El-Saadi upgraded Capricor Therapeutics (NASDAQ: CAPR) from Neutral to Buy with a price target of $21.00.

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Wed, 02 Sep 2026 21:38:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - September 2, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of California.

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Wed, 02 Sep 2026 21:38:00 -0400

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400